Targeting specific proteins to improve treatment responses in head and neck cancer
Targeting EphB4-ephrinB2 to decrease immunosuppression in HNSCC
This study is looking at how a specific pathway in the body can help boost the immune system in patients with high-risk head and neck cancer, aiming to make current treatments like radiation work better for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10915622 on NIH RePORTER |
What this research studies
This research investigates how targeting the EphB4-ephrinB2 pathway can reduce immunosuppression in patients with high-risk head and neck cancer (HNSCC). The study aims to understand how certain immune cells interact with tumor cells and how this interaction can be modified to enhance the effectiveness of existing treatments. By focusing on the tumor microenvironment and the role of specific proteins, the research seeks to improve patient responses to therapies like radiation. Patients may be involved in trials that explore new treatment combinations aimed at overcoming resistance to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-risk head and neck cancer who have not responded well to current treatments.
Not a fit: Patients with early-stage head and neck cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with head and neck cancer by enhancing the effectiveness of immunotherapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways to enhance immune responses in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Karam, Sana D — University of Colorado Denver
- Study coordinator: Karam, Sana D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.